Customer Reception at AMP
PierianDx had a blast with all of its customers at the Partner Sharing Network Reception we hosted during AMP 2016. We are already excited and have been diligently planning this year’s celebration. Join us November 17 at the Red Door, just a short walk from the convention where we will have specialty cocktails and hors d’oeuvres. Festivities begin at 5:30pm.
Join Us at AMP 2017 in Salt Lake City
Corporate Workshops Visit Booth 1613
PierianDx will be conducting two corporate workshops at AMP on November 15. We look forward to seeing you there.
Reaching the Summit: Architecting a Blueprint for Accelerating Precision Oncology
11/15 @ 3:00pm
Workshop Description: Implementing a world-class Precision Medicine program is no easy task. It depends on a range of factors, including strategic planning, executive support, integration of genomic testing into care pathways, accessing genomic data within the electronic medical record, establishing the right testing portfolio, lab workflow optimization and more. In roundtable format, moderated by PierianDx’s Chief Informatics Officer Rakesh Nagarajan, leaders in Precision Medicine will discuss architecting their programs, challenges faced, and key factors for success. Common criteria among their programs will be discussed that enabled the full utilization of genomic testing for advancing precision medicine and creating better outcomes for patients.
Latest Advances in Precision Oncology Insights Utilizing Illumina’s TruSight Tumor 170 Assay
11/15 @ 4:00pm
Workshop Description: Understanding the genetic underpinning of each patient’s tumor is a component of precision oncology, leading to more personalized clinical management. Illumina’s TruSight Tumor 170, a next-generation sequencing-based panel targets SNVs, indels, gene amplifications, gene fusions, splice variants, mRNA expression, and mRNA isoform detection found in 170 cancer-related genes as well as the ability to calculate metrics such as tumor mutation burden and determine evidence for microsatellite instability. A panel will discuss the design of the assay, data analytics, and reasons behind their selection of Illumina’s TST170 targeted cancer assay for tumor profiling at leading cancer centers.
Precision Oncology Roundtable: Ask the Experts about NGS-based Tumor Profiling
October 12, 2017
Featuring Speakers from:
Moffitt Cancer Center
This webinar was an interactive roundtable discussion on the adoption of a commercial gene panel for tumor profiling at several leading US cancer centers.
Our expert panel — Gregory Tsongalis from Dartmouth-Hitchcock, Anthony Magliocco from Moffitt Cancer Center, Ravindra Kolhe from Augusta University, and Rakesh Nagarajan from PierianDx — will specifically discuss their experiences with Illumina’s TruSight Tumor 170 targeted cancer assay.
The TST170 next-generation sequencing-based panel targets single nucleotide variants, indels, gene amplifications, gene fusions, splice variants, mRNA expression, and mRNA isoform detection found in 170 cancer-related genes and also calculates metrics such as tumor mutation burden and determines evidence for microsatellite instability.
Our panelists will discuss the design of the assay, data analytics, and reasons behind their selection of the TST170 assay, and will share details of how it is being utilized within their organizations.
Clinical Genomicist Workspace (CGW): Accelerate Your NGS Testing with an End-to-End Integrated Workspace
September 28, 2017
PierianDx accelerates precision medicine by offering one space to handle a range of genomic testing, from somatic to constitutional, from small panels to whole exome or genome. During this webinar, PierianDx Chief Biomedical Informatics Officer Dr. Rakesh Nagarajan will provide an overview of CGW and illustrate how the industry leading platform seamlessly manages genomic data and workflow for each case, from variant analysis and classification to interpretation, reporting and final sign out. Nagarajan will discuss:
An overview of CGW key features and functions
How PierianDx’s knowledgebase helps to deliver clinically actionable results by leveraging millions of biomedical findings across multiple databases to analyze and classify each detected variant
Examples of actionable clinical reports, both somatic and constitutional
Customer case studies and how CGW has accelerated NGS testing programs, streamlined lab efficiencies and ultimately improved patient care
Building a Best-in-Class Precision Medicine Program: The Moffitt Cancer Center Story
September 14, 2017
Building a world-class precision medicine program takes the right mix of innovative leadership, advanced technology, clinical acumen, and strategic partnerships. During this webinar, Dr. Anthony Magliocco, the Chair of Anatomic Pathology at Moffitt Cancer Center, will share the Moffitt success story – from its pioneering inception to being one of only 47 Comprehensive Cancer Centers as designated by the National Cancer Institute.
Dr. Magliocco will discuss:
Key variables that played an important part in Moffitt Cancer Center’s evolution.
The role of the state-of-the-art Morsani Molecular Diagnostics Laboratory played in that evolution
Pathways to success, unexpected barriers, and an in-depth review of what steps were taken to ensure that the patient comes first
A blueprint for other clinical labs seeking to accelerate precision medicine and NGS testing
Taking Your NGS Testing Program to the Next Level with Enhanced Validation and Interpretation Services
July 13, 2017 at 11:00am CST
The success of any precision medicine program involves the right combination of personnel and technology. PierianDx’s Clinical Genomicist Workspace (CGW) has been the technology platform of choice for clinical labs to seamlessly manage their genomic data and workflow from variant analysis and classification to interpretation, reporting and final sign out. However, the right strategy and clinical resources at the validation and interpretation stages are just as important to that success. During this webinar, PierianDx Chief Bioinformatics Officer Rakesh Nagarajan will discuss ways clinical labs can improve validation and interpretation approaches to enhance report actionability, relevance and throughput. Specifically, Nagarajan will discuss:
Guidelines for improved test validation covering a range of examples
Various validation reports, covering a range of different assays
Understanding the different roles of automated interpretation and clinical interpretation utilizing genomic scientists and medical directors
Case studies of customers who have enhanced their clinical lab capability with PierianDx validation and interpretation services
Accelerating Your NGS Testing Program: Examples and Case Studies
On March 9th, Clinical Genomicist Workspace user and Partner Sharing Network contributor, Dr. Nikoletta Sidiropoulos from University of Vermont Medical Center hosted a webinar with PierianDx exploring various ways clinical labs have established or expanded their NGS testing programs by implementing improved workflow and clinical integration into their organization. Dr. Sidiropoulos shared her experiences and lessons learned as she works to evolve the university’s precision medicine program. Specific examples were shared on how to improve clinical lab workflow, starting with DNA or RNA samples and ending with a report of relevant variants to assist in clinical decision-making. By the end of this webinar, participants will have some real-world examples of how to accelerate their own personalized medicine initiatives from clinical experts in the field.
NGS Roundtable: Ask the Experts about the Future of Clinical NGS Testing
This interactive roundtable discusses established and emerging regulatory, scientific, and medical topics related to next-generation sequencing in the clinical setting. An expert panel of leading pathologists, medical geneticists, and researchers will address genomic testing advances in two thematic areas: 1) scientific and clinical trends in reporting, and 2) clinical lab operations and quality management.
Topics covered by the expert panel include the importance of proficiency testing, both from the regulatory and quality perspective, and technical and clinical advances in using NGS to predict effective immunotherapy and determine tumor mutation load.